A5063940692- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Multiple Myeloma Research and Treatments
- Renal cell carcinoma treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Esophageal Cancer Research and Treatment
- Colorectal and Anal Carcinomas
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
- Cancer therapeutics and mechanisms
- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
ClinAssess (Germany)
2016-2025
Zimmer Biomet (Germany)
2023-2024
Charité - Universitätsmedizin Berlin
2021-2023
Freie Universität Berlin
2021
Humboldt-Universität zu Berlin
2021
Gesellschaft für Klinische Forschung
2014
Howard Hughes Medical Institute
2009
University of Michigan–Ann Arbor
2009
University of Kansas
1993
BackgroundFIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to their gene-signature four different subtypes. Relevance of CMS for the treatment mCRC has yet be defined.Patients and MethodsIn this exploratory analysis, patients were grouped previously published tumor CRC-CMSs. Objective response rates (ORR)...
This trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, controlled, open-label, phase II patients untreated RAS wild-type (WT) metastatic colorectal cancer.The primary end point was objective response rate (ORR) according RECIST (version 1.1). The experimental arm (modified FOLFOXIRI [mFOLFOXIRI] plus panitumumab) considered active if ORR ≥ 75%. compared an estimated 60%...
Abstract Background Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab in KRAS wild-type metastatic colorectal cancer (mCRC) FIRE-3, but no corresponding benefit was found for progression-free survival. This analysis aimed to determine whether cetuximab improves response and versus among response-evaluable patients receiving first-line RAS mCRC the effect of primary tumour side on outcomes. Methods The intent-to-treat population included 593 exon 2 mCRC. Further...
AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus oxaliplatin. This analysis the impact primary tumor location on outcome patients. Left-sided tumors were defined as from rectum to left flexure, while in remaining colon regarded right sided. Overall survival (OS), progression-free (PFS) response rate correlated location. A Cox regression model was used evaluate interaction between KRAS mutation. Of 146...
Abstract Perioperative chemotherapy with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) is a mainstay in the treatment of esophagogastric adenocarcinomas (EGA). Trastuzumab improved survival when added to patients HER‐2‐positive metastatic EGA. We investigated combination trastuzumab FLOT as perioperative locally advanced A multicenter phase II study evaluated efficacy toxicity (24‐hours 5‐FU 2600 mg/m 2 , leucovorin 200 85 mg/mg 50 6 mg/kg then 4 d1, repeated d15 for four...
BackgroundThe German multicenter randomized phase II larynx organ preservation (LOP) trial DeLOS-II was carried out to prove the hypothesis that cetuximab (E) added induction chemotherapy (IC) and radiotherapy improves laryngectomy-free survival (LFS; with preserved larynx) in locally advanced laryngeal/hypopharyngeal cancer (LHSCC).Patients methodsTreatment-naïve patients stage III/IV LHSCC amenable total laryngectomy (TL) were three cycles IC TPF [docetaxel (T) cisplatin (P) 75 mg/m2/day...
3600 Background: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type mCRC patients. We analyzed the efficacy dependent on gender and primary tumor location within RAS population (n=342). Methods: Primary was defined as follows: right sided CRC (RCRC): coecum to hepatic flexure; left (LCRC): splenic flexure rectum. Colon transversum tumors (n=9) were excluded. Differences response (ORR) survival (PFS/OS) both treatment arms...
Purpose The combination of gemcitabine/nab-paclitaxel is an established standard treatment in the first-line metastatic ductal adenocarcinoma pancreas (mPDAC). Afatinib, oral second-generation pan ErbB family tyrosine kinase inhibitor, has shown promising pre-clinical signs pancreatic cancer. aim this phase 1b trial was to determine maximum tolerated dose (MTD) afatinib with patients mPDAC. Methods Treatment naïve (≥18 years) histologically proven mPDAC and good performance status (ECOG 0/1)...
Abstract Purpose: We evaluated additional mutations in RAS wild-type (WT) metastatic colorectal cancer (mCRC) as prognostic and predictive biomarkers for the efficacy of added panitumumab to a 5-fluorouracil plus folinic acid (FU/FA) maintenance pre-specified analysis randomized PanaMa trial. Patients Methods: Mutations (MUT) were identified using targeted next-generation sequencing (NGS; Illumina Cancer Hotspot Panel v2) IHC. RAS/BRAF V600E/PIK3CA/AKT1/ALK1/ERBB2/PTEN MUT HER2/neu...
PURPOSE The FIRE-4 study randomly assigned patients with first-line RAS wild-type ( wt) metastatic colorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab until progression or intolerable toxicity (standard arm) FOLFIRI followed by a switch maintenance treatment using FU bevacizumab (experimental arm). Here, we investigate the relevance of liquid biopsy (LB) BRAF testing compared tissue-based analyses. PATIENTS AND METHODS LBs were taken at...
<h3>Background</h3> Bardet–Biedl syndrome (BBS) is primarily an autosomal recessive disorder characterised by the five cardinal features retinitis pigmentosa, postaxial polydactyly, mental retardation, obesity and hypogenitalism. In addition, renal cysts other anomalies of kidney urinary tract can be present. To date, mutations in 12 <i>BBS</i> genes as well <i>MKS1</i> <i>CEP290</i> have been identified causing BBS. The vast genetic heterogeneity BBS renders molecular diagnosis difficult...
To assess the impact of primary tumor sidedness on outcome patients with metastatic colorectal cancer (mCRC) across treatment lines.Patients FIRE-3 trial (initial FOLFIRI plus either cetuximab or bevacizumab) were separately evaluated according to site differentiating left-sided (LPT) from right-sided tumors (RPT). Efficacy (i.e. progression-free survival (PFS2nd) and overall (OS2nd) second-line therapy) was by Kaplan-Meier method compared log rank test as well Cox regression analyses. All...
The XELAVIRI trial investigated the optimal treatment strategy for patients with untreated metastatic colorectal cancer. We tested noninferiority of initial a fluoropyrimidine plus bevacizumab, followed by addition irinotecan at first progression (arm A) versus upfront use bevacizumab B) in 1:1 randomized, controlled phase III trial.The primary efficacy end point was time to failure (TFS). Given 90% CI, power 70%, and one-sided α .05, margin set 0.8. In case demonstrated TFS, an analysis...
The prognostic and predictive value of carbohydrate antigen 19-9 (CA 19-9) in locally advanced pancreatic cancer (LAPC) has not yet been defined from prospective randomized controlled trials (RCTs).
3510 Background: FIRE-3 compared 1 st -line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wt mCRC patients. CMS is grouping CRCs according to their gene-signature 4 different types. Relevance of for the treatment remains unclear. Methods: Patients were grouped tumor CRC-CMSs. Using ALMAC’s Xcel tissue array, gene signatures samples analyzed. Survival was using Kaplan-Meier estimation and log-rank tests. Hazard ratios (HR) estimated Cox proportional hazard...
Our aim was to investigate the impact of EREG and AREG mRNA expression (by RT-qPCR) in patients with metastatic colorectal cancer (mCRC). In addition, epidermal growth factor receptor (EGFR) immunohistochemistry) as well RAS-and PIK3CA-mutations pyrosequencing) were assessed. Tumors 208 mCRC receiving 5-fluorouracil/leucovorin plus irinotecan (FUFIRI) or oxaliplatin (mIROX) within FIRE-1 trial analyzed for mutations. Molecular characteristics correlated response, progression-free survival...
Abstract Background According to current guidelines, treatment of patients with hepatic oligometastasis in pancreatic cancer is not reflected and systemic chemotherapy recommended those patients. Retrospective data suggest beneficial outcomes oligometastasis, though prospective from clinical trials addressing this particular patient group available. Methods In single arm, phase-2 trial, survival receiving neoadjuvant followed by R0/R1 resection will be compared historic oligometastatic...
The randomized PANAMA trial investigated the efficacy of panitumumab (Pmab) when added to maintenance therapy with fluorouracil and folinic acid (FU/FA) in patients RAS wild-type metastatic colorectal cancer.Following first-line induction six cycles FU/FA oxaliplatin plus Pmab, responding (stable disease or partial complete remission) were randomly assigned (1:1, open-label) treatment either Pmab alone. primary objective was demonstrate superiority progression-free survival (PFS, time from...